Results 161 to 170 of about 2,262 (198)

Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response. [PDF]

Clin Exp Med
Abdelaziz AI, Abdelsameea E, Wahdan SA, Elsherbiny D, Zakaria Z, Azab SS.   +5 more
europepmc   +1 more source

Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors. [PDF]

Biosensors (Basel)
Shcherbakov DN, Mordvinova ED, Trufanov VO, Volkova NV, Meshkova YV, Marenina MK, Zaykovskaya AV, Volosnikova EA, Borisevich SS, Belenkaya SV.   +9 more
europepmc   +1 more source

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination. [PDF]

BMC Med
Zarębska-Michaluk D, Brzdęk M, Tronina O, Janocha-Litwin J, Sitko M, Piekarska A, Klapaczyński J, Parfieniuk-Kowerda A, Sobala-Szczygieł B, Tudrujek-Zdunek M, Laurans Ł, Flisiak R.   +11 more
europepmc   +1 more source

Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response. [PDF]

Sci Rep
Chida T, Ohta K, Noritake H, Matsushita M, Murohisa G, Kageyama F, Sasada Y, Oyaizu T, Tsugiki M, Tamakoshi K, Nakajima T, Suda T, Kawata K.   +12 more
europepmc   +1 more source

Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan. [PDF]

Clin Mol Hepatol
Huang CF, Dai CY, Lin YH, Wang CW, Jang TY, Liang PC, Lin TC, Tsai PC, Wei YJ, Yeh ML, Hsieh MY, Huang CK, Huang JF, Chuang WL, Yu ML.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Asunaprevir/daclatasvir

Reactions Weekly, 2016
  +15 more sources

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Lancet, The, 2014
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus ...
Cheng-Yuan Peng, Stanislas Pol
exaly   +2 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2018
  +12 more sources

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection [PDF]

Journal of Clinical Pharmacology, 2018
Tushar Garimella
exaly   +2 more sources